|

Relacorilant Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: CORT125134

Pipeline

Phase 2: 2

Top Sponsors

  • University of Chicago1
  • Corcept Therapeutics1

Indications

  • Cancer2
  • Carcinoma, Pancreatic Ductal1
  • Adenocarcinoma1
  • Prostate Adenocarcinoma1
  • Prostate Cancer1

Scottsdale, Arizona1 trial

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Site 02

Phase 2

Chicago, Illinois1 trial

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

University of Chicago Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.